Ocular Therapeutix, Inc. (OCUL): Price and Financial Metrics


Ocular Therapeutix, Inc. (OCUL): $10.85

0.27 (+2.55%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OCUL to Watchlist
Sign Up

Industry: Biotech


Ranked

of 504

in industry

OCUL POWR Grades


  • Quality is the dimension where OCUL ranks best; there it ranks ahead of 57.02% of US stocks.
  • OCUL's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
  • OCUL ranks lowest in Stability; there it ranks in the 5th percentile.

OCUL Stock Summary

  • OCUL's price/sales ratio is 25.74; that's higher than the P/S ratio of 91.88% of US stocks.
  • As for revenue growth, note that OCUL's revenue has grown 344.51% over the past 12 months; that beats the revenue growth of 97.62% of US companies in our set.
  • Ocular Therapeutix Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -19.93%, greater than the shareholder yield of only 13.41% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Ocular Therapeutix Inc are WISA, TTOO, GPRO, ACMR, and KN.
  • OCUL's SEC filings can be seen here. And to visit Ocular Therapeutix Inc's official web site, go to www.ocutx.com.

OCUL Valuation Summary

  • In comparison to the median Healthcare stock, OCUL's price/sales ratio is 557.89% higher, now standing at 25.
  • Over the past 86 months, OCUL's price/sales ratio has gone down 2156.5.
  • Over the past 86 months, OCUL's EV/EBIT ratio has gone up 6.

Below are key valuation metrics over time for OCUL.

Stock Date P/S P/B P/E EV/EBIT
OCUL 2021-08-31 25.0 10.1 -7.9 -7.0
OCUL 2021-08-30 25.5 10.2 -8.0 -7.1
OCUL 2021-08-27 26.1 10.5 -8.2 -7.4
OCUL 2021-08-26 25.2 10.2 -7.9 -7.1
OCUL 2021-08-25 25.0 10.1 -7.9 -7.0
OCUL 2021-08-24 24.5 9.9 -7.7 -6.8

OCUL Growth Metrics

  • The 5 year cash and equivalents growth rate now stands at 20.49%.
  • Its 3 year net income to common stockholders growth rate is now at -47.26%.
  • Its 2 year price growth rate is now at -11.29%.
OCUL's revenue has moved up $30,312,000 over the prior 33 months.

The table below shows OCUL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 32.285 -57.319 -102.916
2021-03-31 22.136 -52.059 -131.003
2020-12-31 17.403 -53.554 -155.636
2020-09-30 12.31 -66.775 -96.041
2020-06-30 7.263 -72.661 -102.875
2020-03-31 6.344 -77.046 -90.76

OCUL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OCUL has a Quality Grade of C, ranking ahead of 57.02% of graded US stocks.
  • OCUL's asset turnover comes in at 0.155 -- ranking 219th of 677 Pharmaceutical Products stocks.
  • CASI, ONVO, and DRNA are the stocks whose asset turnover ratios are most correlated with OCUL.

The table below shows OCUL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.155 0.903 -1.479
2021-03-31 0.125 0.903 -1.953
2020-12-31 0.129 0.880 -2.245
2020-09-30 0.138 0.818 -1.315
2020-06-30 0.084 0.642 -1.377
2020-03-31 0.077 0.525 -1.196

OCUL Price Target

For more insight on analysts targets of OCUL, see our OCUL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $23.43 Average Broker Recommendation 1.43 (Moderate Buy)

OCUL Stock Price Chart Interactive Chart >

Price chart for OCUL

OCUL Price/Volume Stats

Current price $10.85 52-week high $24.30
Prev. close $10.58 52-week low $7.50
Day low $10.50 Volume 766,900
Day high $10.86 Avg. volume 940,172
50-day MA $10.94 Dividend yield N/A
200-day MA $15.79 Market Cap 830.93M

Ocular Therapeutix, Inc. (OCUL) Company Bio


Ocular Therapeutix is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. The company was founded in 2006 and is based in Bedford, Massachusetts.


OCUL Latest News Stream


Event/Time News Detail
Loading, please wait...

OCUL Latest Social Stream


Loading social stream, please wait...

View Full OCUL Social Stream

Latest OCUL News From Around the Web

Below are the latest news stories about Ocular Therapeutix Inc that investors may wish to consider to help them evaluate OCUL as an investment opportunity.

Ocular Therapeutix™ Appoints Merilee Raines to Its Board of Directors

BEDFORD, Mass., September 22, 2021--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Merilee Raines to the Company’s Board of Directors effective September 20, 2021.

Yahoo | September 22, 2021

Ocular Therapeutix Updates Monthly In-Market Unit Sales of DEXTENZA® Billable Inserts

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera

Business Wire | September 13, 2021

Ocular Therapeutix™ Updates Monthly In-Market Unit Sales of DEXTENZA® Billable Inserts

BEDFORD, Mass., September 13, 2021--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported in-market unit sales of DEXTENZA® billable inserts of 6,924 and 9,321 in July and August, respectively, as part of the Company’s corporate presentation at the H.C. Wainwright 23rd Annual Global Investment Conference. August units represent the second hig

Yahoo | September 13, 2021

Ocular Therapeutix™ to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

BEDFORD, Mass., September 07, 2021--Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held from September 13-15, 2021.

Yahoo | September 7, 2021

Investing in Ocular Therapeutix (NASDAQ:OCUL) five years ago would have delivered you a 61% gain

Ocular Therapeutix, Inc. ( NASDAQ:OCUL ) shareholders might be concerned after seeing the share price drop 27% in the...

Yahoo | September 6, 2021

Read More 'OCUL' Stories Here

OCUL Price Returns

1-mo 2.75%
3-mo -23.00%
6-mo -36.06%
1-year 38.75%
3-year 63.90%
5-year 51.96%
YTD -47.58%
2020 424.05%
2019 -0.75%
2018 -10.56%
2017 -46.83%
2016 -10.67%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9011 seconds.